


CLAIMS

We claim:

1. A compound of formula I:





I

or a pharmaceutically acceptable salt, or mixtures thereof,

wherein:

W is:



wherein each R₆ is independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-cycloalkyl- or cycloalkenyl-,

[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-, or
wherein up to 3 aliphatic carbon atoms in each R₆
may be optionally replaced with S, -S(O)-, -S(O)₂-,
-O-, -N-, or -N(H)- in a chemically stable
arrangement;

wherein R₆ may be optionally substituted with up
to 3 J substituents; or

two R₆ groups, together with the nitrogen atom to
which they are bound, may optionally form a 5- to 6-
membered aromatic or a 3- to 7-membered saturated or
partially unsaturated ring system wherein up to 3
ring atoms may be optionally replaced with N, NH, O,
S, SO, and SO₂, wherein said ring system may be
optionally fused to a (C6-C10)aryl,
(C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a
(C3-C10)heterocyclyl, wherein any ring has up to 3
substituents selected independently from J;

wherein each R₈ is independently -OR'; or the R₈
groups together with the boron atom, may optionally
form a (C3-C10)-membered heterocyclic ring wherein
each R₈ is independently -OR'; or the R₈ groups
together with the boron atom, may optionally form a
(C3-C10)-membered heterocyclic ring having, in
addition to the boron, up to 3 ring atoms optionally
replaced with N, NH, O, S, SO, and SO₂;

J is halogen, -OR', -NO₂, -CN, -CF₃, -OCF₃, -R', oxo,
thioxo, =N(R'), =N(OR'), 1,2-methylenedioxy, 1,2-
ethylenedioxy, -N(R')₂, -SR', -SOR', -SO₂R', -SO₂N(R')₂,
-SO₃R', -C(O)R', -C(O)C(O)R', -C(O)C(O)OR',
-C(O)C(O)NR', -C(O)CH₂C(O)R', -C(S)R', -C(S)OR',
-C(O)OR', -OC(O)R', -C(O)N(R')₂, -OC(O)N(R')₂,
-C(S)N(R')₂, -(CH₂)₀₋₂NHC(O)R', -N(R')N(R')COR',
-N(R')N(R')C(O)OR', -N(R')N(R')CON(R')₂, -N(R')SO₂R',
-N(R')SO₂N(R')₂, -N(R')C(O)OR', -N(R')C(O)R',

$-N(R')C(S)R'$, $-N(R')C(O)N(R')_2$, $-N(R')C(S)N(R')_2$,
 $-N(COR')COR'$, $-N(OR')R'$, $-C(=NH)N(R')_2$, $-C(O)N(OR')R'$,
 $-C(=NOR')R'$, $-OP(O)(OR')_2$, $-P(O)(R')_2$, $-P(O)(OR')_2$, or
 $-P(O)(H)(OR')$; wherein;

R' is independently selected from:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, and

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 5 atoms in R' may be optionally and
independently substituted with J;

wherein two R' groups bound to the same atom may
optionally form a 5- to 6-membered aromatic or a 3-
to 7-membered saturated or partially unsaturated
ring system wherein up to 3 ring atoms may be
optionally replaced with a heteroatom independently
selected from N, NH, O, S, SO, and SO₂, wherein said
ring system may be optionally fused to a (C6-
C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or
a (C3-C10)heterocyclyl, wherein any ring has up to 3
substituents selected independently from J;

R₅ and R₅' are each independently hydrogen or (C1-C12)-
aliphatic, wherein any hydrogen may be optionally
replaced with halogen; wherein any terminal carbon atom
of R₅ may be optionally substituted with sulfhydryl or
hydroxy; or R₅ is Ph or -CH₂Ph and R₅' is H, wherein
said Ph or -CH₂Ph group may be optionally substituted

with up to 3 substituents independently selected from J; or

R₅ and R₅ together with the atom to which they are bound may optionally form a 3- to 6-membered saturated or partially unsaturated ring system wherein up to 2 ring atoms may be optionally replaced with N, NH, O, SO, or SO₂; wherein said ring system has up to 2 substituents selected independently from J;

R₂, R₄, and R₇ are each independently:

hydrogen-,

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or

(C6-C10)-aryl-(C1-C12)-aliphatic-;

wherein up to two aliphatic carbon atoms in each of R₂, R₄, and R₇ may be optionally replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)- in a chemically stable arrangement;

wherein each of R₂, R₄, and R₇ may be independently and optionally substituted with up to 3 substituents independently selected from J;

R₁ and R₃ are each independently:

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-(C1-C12)aliphatic-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in each of R₁ and R₃ may be optionally replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)- in a chemically stable arrangement;

wherein each of R₁ and R₃ may be independently and optionally substituted with up to 3 substituents independently selected from J;

R₉, R_{9'}, R₁₀, and R_{10'} are each independently -X-Y-Z;

X is a bond, -C(H)(R₆)-, -O-, -S-, or -N(R₁₁)-;

R₁₁ is:

hydrogen-,
(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl- or cycloalkenyl-,
[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-
aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-,

wherein up to 3 aliphatic carbon atoms in each R₁₁
may be optionally replaced with S, -S(O)-, -S(O)₂-,
-O-, -N-, or -N(H)- in a chemically stable
arrangement;

wherein R₁₁ may be optionally substituted with up
to 3 J substituents; or

wherein R₁₁ and Z together with the atoms to which
they are bound, optionally form a nitrogen
containing 5-7-membered mono- or 6-11-membered
bicyclic ring system optionally substituted with up
to 3 J substituents, wherein up to 3 ring atoms in
said ring system may be optionally replaced with O,
NH, S, SO, or SO₂ in a chemically stable arrangement;

Y is a bond, -CH₂-, -C(O)-, -C(O)C(O)-, -S(O)-, S(O)₂-, or
-S(O)(NR₁₂)-;

R₁₂ is:

hydrogen-,
(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-cycloalkyl- or cycloalkenyl-,
[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-
aliphatic-,

(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-,

wherein up to 3 aliphatic carbon atoms in each R₁₂
may be optionally replaced with S, -S(O)-, -S(O)₂-,
-O-, -N-, or -N(H)-, in a chemically stable
arrangement;

wherein R₁₂ may be optionally substituted with up
to 3 J substituents;

Z is:

hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in Z may
be optionally replaced with S, -S(O)-, -S(O)₂-, -O-,
-N-, or -N(H)-, in a chemically stable arrangement;

wherein any ring may be optionally fused to a
(C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl,
or (C3-C10)heterocyclyl;

wherein Z may be independently and optionally
substituted with up to 3 substituents independently
selected from J;

V is -C(O)-, -S(O)-, or -S(O)₂-;

R is -C(O)-, -S(O)-, -S(O)₂-, -N(R₁₂)-, -O-, or a bond;

T is:

(C1-C12)-aliphatic-;
(C6-C10)-aryl-;
(C6-C10)-aryl-(C1-C12)aliphatic-;
(C3-C10)-cycloalkyl or -cycloalkenyl-;
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-;
(C3-C10)-heterocyclyl-;
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-;
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in T may be replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement;

wherein each T may be optionally substituted with up to 3 J substituents; or

T is selected from -N(R₆)(R₆); and

R₆ is

hydrogen-;
(C1-C12)-aliphatic-;
(C6-C10)-aryl-;
(C6-C10)-aryl-(C1-C12)aliphatic-;
(C3-C10)-cycloalkyl- or cycloalkenyl-;
[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-
aliphatic-;
(C3-C10)-heterocyclyl-;
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-;
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-, or



wherein up to 3 aliphatic carbon atoms in each R₆ may be optionally replaced with S, -S(O)-, -S(O)₂-,

-O-, -N-, or -N(H)- in a chemically stable arrangement;

wherein R_6 may be optionally substituted with up to 3 J substituents; or

R_6 and R_6' , together with the nitrogen atom to which they are bound, may optionally form a (C3-C10)-heterocyclic ring system wherein said ring system may be optionally substituted with up to 3 substituents independently selected from J.

2. The compound according to claim 1, wherein the



in R_9 , R_{10} , and R_{10}' , X and Y are both a bond and Z is hydrogen; and in R_9 ;

X is a bond;

Y is a bond, $-CH_2-$, or $-C(O)-$; and

Z is (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in Z may be optionally replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement;

wherein any ring may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein Z may be independently and optionally substituted with up to 3 substituents independently selected from J.

3. The compound according to claim 2, wherein in R₉;

X is a bond;

Y is a bond; and

Z is (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in Z may be optionally replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement;

wherein any ring may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein Z may be independently and optionally substituted with up to 3 substituents independently selected from J.

4. The compound according to claim 3, wherein in R₉;

X is a bond;

Y is a bond; and

Z is (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,


[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-, or

(C6-C10)-aryl-(C1-C12)aliphatic-,


wherein up to three aliphatic carbon atoms in Z may
be optionally replaced with S, -S(O)-, -S(O)₂-, -O-,
-N-, or -N(H)-, in a chemically stable arrangement;

wherein Z may be independently and optionally
substituted with up to 3 substituents independently
selected from J.

5. The compound according to claim 4, wherein R₉ is



6. The compound according to claim 5, wherein R₉ is



7. The compound according to claim 6, wherein R₉ is
ethyl.

8. The compound according to claim 1, wherein in R_9 , R_{10} , and $R_{10'}$, X and Y are both a bond and Z is hydrogen; and in R_9 ;

X is a bond;

Y is $-C(O)-$; and

Z is (C1-C12)-aliphatic-, or

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-;

wherein up to three aliphatic carbon atoms in Z may be optionally replaced with S, $-S(O)-$, $-S(O)_2-$, $-O-$, $-N-$, or $-N(H)-$, in a chemically stable arrangement;

wherein any ring may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein Z may be independently and optionally substituted with up to 3 substituents independently selected from J.

9. The compound according to claim 8, wherein Z is $-O-(C1-C6)$ -aliphatic or $-N(R')_2$, wherein the two R' groups bound to the nitrogen atom may optionally form a 3- to 7-membered saturated or partially unsaturated ring system wherein up to 3 ring atoms may be optionally replaced with a heteroatom independently selected from N, NH, O, S, SO, and SO_2 , wherein said ring system may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.

10. The compound according to claim 8, wherein Z is $-N(R')_2$, wherein the two R' groups bound to the nitrogen atom may optionally form a 3- to 7-membered saturated or partially unsaturated ring system wherein up to 3 ring atoms may be optionally replaced with a heteroatom

independently selected from N, NH, O, S, SO, and SO₂, wherein said ring system may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J.

11. The compound according to claim 1, wherein in R₉, and R₁₀, X and Y are a bond and Z is hydrogen; and in each of R₉, and R₁₀, independently;

X is a bond;

Y is a bond; and

Z is (C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to three aliphatic carbon atoms in Z may be optionally replaced with S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement;

wherein any ring may be optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;

wherein Z may be independently and optionally substituted with up to 3 substituents independently selected from J.

12. The compound according to claim 11, wherein Z, in each of R₉, and R₁₀, independently, is

(C1-C12)-aliphatic-,

(C3-C10)-cycloalkyl- or -cycloalkenyl-, or
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-;

wherein up to three aliphatic carbon atoms in Z may
be optionally replaced with S, -S(O)-, -S(O)₂-, -O-,
-N-, or -N(H)-, in a chemically stable arrangement;

wherein Z may be independently and optionally
substituted with up to 3 substituents independently
selected from J.

13. The compound according to claim 12, wherein Z,
in each of R₉' and R₁₀', independently, is (C1-C6)-
aliphatic-.

14. The compound according to claim 1, wherein in
R₁₀, and R₁₀', X and Y are a bond and Z is hydrogen; and in
each of R₉ and R₉';


X is a bond,

Y is a bond, and

Z is (C1-C6)-aliphatic-,

wherein Z may be independently and optionally
substituted with up to 3 substituents independently
selected from J.


15. The compound according to any one of claims 1-
14, wherein W is:




wherein in the W, the NR₆R₆ is selected from -NH-(C1-C6
aliphatic), -NH-(C3-C6 cycloalkyl), -NH-CH(CH₃)-aryl, or
-NH-CH(CH₃)-heteroaryl, wherein said aryl or said

heteroaryl is optionally substituted with up to 3 halogens.


16. The compound according to claim 15, wherein in the W, the NR_6R_6 is:



17. The compound according to claim 16, wherein in the W, the NR_6R_6 is:




18. The compound according to claim 17, wherein in the W, the NR_6R_6 is:




19. The compound according to claim 18, wherein in the W, the NR_6R_6 is:

[illegible]


25. The compound according to claim 24, wherein R₃ is:




26. The compound according to claim 25, wherein R₃ is:



27. The compound according to any one of claims 1-26, wherein R₁ is:




28. The compound according to claim 27, wherein R₁ is:




29. The compound according to claim 18, wherein R₁ is isopropyl or cyclohexyl.

30. The compound according to claim 1, wherein the




radical is:



wherein:

R_6 , R_6' , R_7 , and R_{12} , are as defined in claim 1.

31. The compound according to claim 30, wherein
in the



radical;

R₆, and R₇ are both hydrogen;

R_6 is:

(C1-C12)-aliphatic-;

(C6-C10)-aryl-,

(C6-C10)-aryl-(C1-C12)aliphatic-,

(C3-C10)-cycloalkyl or -cycloalkenyl-,

[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-
aliphatic-,

(C3-C10)-heterocyclyl-,

(C3-C10)-heterocyclcyl-(C1-C12)-aliphatic-,

(C5-C10)-heteroaryl-, or

(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;

wherein up to 3 aliphatic carbon atoms in R₆ may be optionally replaced by S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement; and

wherein R_6 may be optionally substituted with up to 3 substituents independently selected from J;
and

R_{12} is as defined in claim 1.

32. The compound according to claim 31, wherein;
 R_6 is:


(C1-C12)-aliphatic-;
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C3-C10)-cycloalkyl or -cycloalkenyl-;

wherein up to 3 aliphatic carbon atoms in R_6 may be optionally replaced by S, -S(O)-, -S(O)₂-, -O-, -N-, or -N(H)-, in a chemically stable arrangement;


wherein R_6 may be optionally substituted with up to 3 substituents independently selected from J;
and

R_{12} is as defined in claim 1.


33. The compound according to claim 32, wherein the radical is:



34. The compound according to claim 33, wherein the



radical is:



35. The compound according to any one of claims 1-29, wherein;

V is -C(O)-; and
R is a bond.

36. The compound according to any one of claims 1-29, wherein;

V is -C(O)-;

R is a bond; and

T is:


(C3-C10)-heterocyclyl- or (C5-C10)heteroaryl-;

wherein each T is optionally substituted with up to 3 J substituents.

37. The compound according to claim 36, wherein T is (C5-C6)heterocyclyl- or (C5-C6)heteroaryl-;

wherein each T is optionally substituted with up to 3 J substituents.


38. The compound according to claim 37, wherein T is:



wherein:










Z' is independently O, S, NR', or C(R')₂.











39. The compound according to claim 38, wherein T is:






















40. The compound according to claim 1, wherein the compound is:











1	
2	
3	
4	
5	
6	
7	
8	

9	
10	
11	
12	
13	
14	
15	
16	
17	










18	
19	
20	
21	
22	
23	
24	
25	
26	
27	




28	
29	
30	
31	
32	
33	
34	
35	
36	
37	

38	
39	
40	
41	
42	
43	
44	
45	
46	

47	
48	
49	
50	
51	
52	
53	
54	
55	
56	

57	
58	
59	
60	
61	
62	
63	
64	
65	

66	
67	
68	
69	
70	
71	
72	
73	
74	

75	
76	
77	

41. A pharmaceutical composition comprising a compound according to any one of claims 1-40 or a pharmaceutically acceptable salt or mixtures thereof in an amount effective to inhibit a serine protease; and a acceptable carrier, adjuvant or vehicle.

42. The composition according to claim 41, wherein said composition is formulated for administration to a patient.

43. The composition according to claim 42, wherein said composition comprises an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; and a cytochrome P-450 inhibitor; or combinations thereof.

44. The composition according to claim 41, wherein said immunomodulatory agent is α -, β -, or γ -interferon or thymosin; said antiviral agent is ribavirin, amantadine, or telbivudine; or said inhibitor of another target in

the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.

45. The composition according to claim 43, wherein said cytochrome P-450 inhibitor is ritonavir.

46. A method of inhibiting the activity of a serine protease comprising the step of contacting said serine protease with a compound according to any one of claims 1-40.

47. The method according to claim 46, wherein said serine protease is an HCV NS3 protease.

48. A method of treating an HCV infection in a patient comprising the step of administering to said patient a composition according to claim 42.

49. The method according to claim 48, comprising the additional step of administering to said patient an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; or combinations thereof; wherein said additional agent is administered to said patient as part of said composition according to claim 42 or as a separate dosage form.

50. The method according to claim 49, wherein said immunomodulatory agent is α -, β -, or γ -interferon or thymosin; said antiviral agent is ribavarin or amantadine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.

52. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a composition according to claim 41.

53. The method according to claim 52, wherein said sample or equipment is selected from blood, other body fluids, biological tissue, a surgical instrument, a surgical garment, a laboratory instrument, a laboratory garment, a blood or other body fluid collection apparatus; a blood or other body fluid storage material.

54. The method according to claim 53, wherein said body fluid is blood.